CES2、CA19-9表达与结直肠癌患者临床病理特征及化疗预后关系的分析

Correlation between expression of CES2 and CA19-9 and clinicopathological features and chemotherapeutic prognosis of colorectal cancer patients

目的观察羧酸酯酶2(CES2)及糖链抗原19-9(CA19-9)在结直肠癌组织中的表达,并分析两者与患者临床病理特征及化疗预后的关系。方法采用免疫组织化学方法检测134例结直肠癌组织、30例腺瘤组织、30例正常结直肠组织中CES2、CA19-9表达情况,分析两者表达与结直肠癌患者临床病理特征和预后的关系。选择接受FOLFIRI化疗方案的69例结直肠癌患者,重点探讨CES2与患者FOLFIRI化疗近期疗效的关系。结果结直肠癌组中CES2高表达者占52.99%,CA19-9高表达者占79.85%,但与腺瘤及正常结直肠组织比较,差异均无统计学意义(均P> 0.05)。CES2高表达与患者性别、年龄、肿瘤大体类型、T分期、N分期、M分期、Dukes分期、肿瘤大小及分化程度均无关(均P> 0.05)。CA19-9高表达与性别、年龄、肿瘤大体类型、T分期、M分期、Dukes分期、肿瘤大小及分化程度均无关(均P> 0.05)。N1～2期患者中CA19-9高表达者比例高于N0期患者,差异有统计学意义(P <0.05)。CES2高表达患者累积生存时间长于低表达患者(P <0.05)。CA19-9高表达者累积生存时间与低表达者比较,差异无统计学意义(P> 0.05)。接受FOLFIRI化疗方案者中,CES2高表达者近期疗效优于低表达者,差异有统计学意义(P <0.05)。结论 CA19-9与结直肠癌患者淋巴结转移情况有关;CES2与结直肠癌患者临床病理特征无关,但可为化疗预后评估提供一定参考。

Objectives To investigate the expression of carboxylesterase 2 (CES2) and carbohydrate antigen 19-9 (CA19-9) in colorectal cancer tissues, and to determine their correlation with clinicopathological features and chemotherapeutic prognosis of colorectal cancer patients. Methods The expression of CES2 and CA19-9 was detected by immunohistochemistry in 134 patients of colorectal cancer, 30 of adenoma, and 30 normal colorectal tissue. We analyzed the correlations between their expression and clinicopathological features and chemotherapeutic prognosis of colorectal cancer patients. We also analyzed the relationship between CES and short-term effect of FOLFIRI chemotherapy in 69 patients who received such chemotherapy. Results High expression of CES2 and CA19-9 was found in 52.99% and 79.85%, respectively, patients with colorectal cancer. There was no significant difference compared with adenoma and normal colorectal tissue (P > 0.05). High expression of CES2 has no significant correlation with patients’sex, age, type of tumor, T stage, N stage, M stage, Dukes stage, size of the tumor and degree of differentiation (P > 0.05). High expression of CA19-9 has no significant correlation with patients’sex, age, gross classification, T stage, M stage, Dukes stage, size of the tumor and degree of differentiation (P > 0.05). Expression of CA19-9 was significantly higher in N1~2 stage patients than in N0 stage patients (P < 0.05). Patients with high expression of CES2 had longer cumulative survival time than those with low expression (P < 0.05). There was no significant difference in cumulative survival time between patients with high and low expression of CA19-9 (P > 0.05). In patients who received FOLFIRI chemotherapy, short-term efficacy was significantly better in patients with high CES2 expression than those with low expression (P < 0.05). Conclusion CA19- 9 was correlated with lymph node metastasis in colorectal cancer patients, CES2 had no correlation with clinicopathological features but it could provide some reference for chemotherapeutic prognosis evaluation.